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The Capsid Binder Vapendavir and the Novel Protease Inhibitor SG85
Inhibit Enterovirus 71 Replication
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Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgiuma; Biota Pharmaceuticals Inc., Notting Hill, Vic., Australiab; Institute of Biochemistry,
Center for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germanyc
Antivirals against enterovirus 71 (EV71) are urgently needed.We demonstrate that the novel enteroviral protease inhibitor (PI)
SG85 and capsid binder (CB) vapendavir efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are represen-
tative of the different genogroups A, B, and C. The PI rupintrivir, the CB pirodavir, and the host-targeting compound envi-
roxime, which were included as reference compounds, also inhibited the replication of all isolates. Remarkably, the CB com-
pound pleconaril was devoid of any anti-EV71 activity. An in silico docking study revealed that pleconaril—unlike vapendavir
and pirodavir—lacks essential binding interactions with the viral capsid. Vapendavir and SG85 (or analogues) should be further
explored for the treatment of EV71 infections. The data presented here may serve as a reference when developing yet-novel
inhibitors.
Enterovirus 71 (EV71) is a nonenveloped, single-stranded, pos-itive-sense RNA virus that belongs to the family Picornaviri-
dae. The virus is, together with coxsackie A viruses (CVA), the
major causative agent of hand, foot, and mouth disease (HFMD),
a mild and self-limiting disease that affects mostly children
younger than 5 years old.However, in some patients the virusmay
cause severe, potentially lethal complications such as aseptic
meningitis, encephalitis, pulmonary edema, and viral myocar-
ditis (1, 2). In recent years, EV71 has been shown to cause in
parts of Asia large outbreaks of HFMD that are associated with
severe neurological conditions such as encephalitis and acute
flaccid paralysis (3).
Medical care of patients with EV71 infections is symptomatic
and depends on the clinical stage of the disease. Patients with
uncomplicated HFMD can use paracetamol for pain relief,
whereas severe cases of HFMD, i.e., those with central nervous
system (CNS) involvement, may be treated by administration of
intravenous immunoglobulin (IVIG) (4, 5). When the brainstem
is affected, intravenous fluid therapy and the use of inotropes to
support cardiac function should be considered. Phase III clinical
vaccine trials have recently been completed (6–8). There are, how-
ever, no antivirals available for the treatment or prophylaxis of
EV71 infections. Such anti-EV71 drugs are urgently needed.
Since EV71 consists of different (sub)genogroups, it will be
important to have a representative panel of isolates against which
the activity of novel compounds can be assessed. Marked differ-
ences in susceptibility of enteroviruses to antiviral drugs have been
reported. For example, the capsid binder pleconaril is active
against most rhino- and coxsackievirus strains but is, however,
completely inactive against other rhino- and enteroviruses (9, 10).
Six enterovirus inhibitors were included in this study: (i) the
novel 3C protease inhibitor (PI) SG85 (11) and the PI rupintrivir
(12); (ii) the host cell-targeting compound enviroxime (13); and
(iii) three capsid binding compounds, i.e., pleconaril, pirodavir,
and vapendavir (14–16). Vapendavir is currently in clinical devel-
opment for the treatment or prophylaxis of rhinovirus infections
in patients at risk of rhinovirus-mediated exacerbation of their
underlying respiratory disease(s) (NCT01175226). The potential
antiviral activity of these compounds against a panel of 21 EV71
strains or isolates was assessed in a cell-based multicycle cytopathic
effect (CPE) reduction assay using an [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt] (MTS) readout, as described previously (17). The EV71
strains were selected such that all three genogroups, A, B, and C,
were represented in the panel as determined on the basis of their
VP1 sequence (see Fig. S1 in the supplemental material).
The novel PI SG85 potently inhibited the replication of all 21
EV71 strains, with 50% effective concentrations (EC50s) varying
between 0.039Mand 0.200M(Table 1; also see Table S1 in the
supplemental material). Rupintrivir did so with EC50s ranging
between 0.003 M and 0.012 M. All isolates proved markedly
sensitive to the antiviral activity of these two PIs, although strains
belonging to subgenogroup B5 proved somewhat less sensitive
than those belonging to subgenogroups C2 and C4. Enviroxime,
which was included as a reference compound (and which inhibits
viral replication by targeting cellular phosphoinositol 4-kinase
III [PI4KIII], a kinase essential for picornavirus replication
[18]) inhibited the replication of all EV71 strains with EC50s be-
tween 0.070 M and 0.458 M.
A remarkable difference in activity was noted for the capsid
binding compounds vapendavir, pirodavir, and pleconaril.
Whereas vapendavir and the analogue pirodavir inhibited EV71
replication of all isolates (average EC50s of 0.7 M for vapendavir
and 0.5 M for pirodavir), pleconaril was completely devoid of
any antiviral activity. The antiviral activity of the pleconaril batch
that was used for this study was confirmed against coxsackievirus
A9 (strain Bozek) and poliovirus (type 3 Sabin) (with EC50s of
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0.027 M and 0.341 M, respectively, which are comparable to
published values) (14, 19).
Conflicting data exist regarding the antiviral activity of pleco-
naril against EV71. In one study, antiviral activity of pleconaril
was reported in EV71-infectedmice (20). Other studies, however,
reported a lack of in vitro anti-EV71 activity of pleconaril (21–23).
Moreover, inconsistent data on the potential efficacy of pleconaril
in the treatment of enteroviral infections in humans have been
reported (24–26). These incompatible data were one of the rea-
sons to perform this study. We now present conclusive evidence
that pleconaril is inactive against EV71 strains of all three geno-
groups. Hence, pleconaril should no longer be considered for the
(compassionate) treatment of enteroviral infections, caused by
EV71. We recently established a mouse model of EV71-induced
encephalitis in adult SCIDmice (unpublished results). Thismodel
will be ideally suited to assess whether compounds such as vapen-
davir and SG85 have, in contrast to pleconaril, any protective ac-
tivity in vivo against EV71 infections.
To explain the marked difference in susceptibility of EV71 to
pleconaril (lack of activity) on the one hand and vapendavir and
pirodavir (robust activity) on the other hand, a modeling study
was performed. The potential interaction of the compounds in the
pocket under the floor of the receptor binding canyon was ex-
plored (detailedmethods are given in the supplemental material).
Docking studies revealed that vapendavir and pirodavir have
stronger binding interactions with the viral capsid at the opening
of the canyon than pleconaril. When the interactions of pirodavir
and vapendavir were compared to those ofWIN51711 (the capsid
binding compound which was cocrystallized with the EV71 cap-
sid), a remarkable similarity was noted. All threemolecules extend
their binding in the direction of the pore and anchor via a hydro-
gen bond (either with Asp112 or with Ile113) (Fig. 1). In contrast,
pleconaril appears unable to reach that far in the EV71 pocket;
hence, anchoring is not possible, which may explain the lack of
antiviral activity. Knowledge of the precise interactions between
the viral capsid and capsid binding compounds may help to de-
velop novel and yet more potent antivirals. A novel class of EV71
capsid binders was recently reported which were designed based
on the crystal structure of the EV71 capsid (27). In that particular
study, cocrystals of the EV71 capsid with the compounds revealed
an interaction with Asp112 and/or Ile113, underlining the impor-
tance of these interactions and corroborating the findings of our
modeling study.
In conclusion, we established a reference panel of EV71 isolates
representative for the different (sub)genogroups. The novel cap-
sid binder vapendavir (currently under clinical study for the treat-
ment of rhinovirus infections in high-risk patients), its analogue
pirodavir, and the novel PI SG85 efficiently inhibit EV71 replica-
tion. In contrast, pleconaril was completely devoid of activity
against EV71,whichwas explained in amolecularmodeling study.
This information will be important for the design of novel EV71
capsid binding compounds. Vapendavir and SG85 (or analogues)
may be further developed for the treatment of EV71 infection.
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FIG 1 Docking result of pirodavir (magenta carbons), pleconaril (yellow car-
bons), and vapendavir (gray carbons) in the EV71 homologue model VP1
pocket (created from 3ZFE, green carbons in residues, light blue surface),
superimposed onto the canyon of the 3ZFF structure (residues having gray
carbons) containing theWIN51711 inhibitor (cyan). The surface of the open-
ing of the canyon is colored yellow; residue labels have been added for residues
in hydrophobic contact with the inhibitors.







SG85 Rupintrivir Vapendavir Pirodavir Pleconaril
A 0.080 0.015 0.006 0.003 0.098 0.026 0.842 0.325 0.361 0.209 262
B2 0.200 0.070 0.012 0.004 0.148 0.072 0.671 0.321 0.727 0.223 262
B5 0.184 0.026 0.010 0.001 0.198 0.078 0.498 0.236 0.484 0.170 262
C2 0.069 0.032 0.005 0.002 0.248 0.166 0.957 0.074 0.491 0.102 262
C4 0.117 0.012 0.007 0.001 0.196 0.096 0.739 0.248 0.513 0.090 262
a Data are the means standard deviations of all EV71 strains included in the virus panel which group to the designated genogroup (1 isolate for genogroup A, 1 for B2, 6 for B5, 3
for C2, and 10 for C4). Per strain, at least 3 independently obtained EC50s were used.
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